Beijing Centers for Disease Control and Preventative Medical Research, Beijing Center for Disease Prevention and Control, China.
NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, China.
Jpn J Infect Dis. 2023 May 24;76(3):183-190. doi: 10.7883/yoken.JJID.2022.476. Epub 2023 Jan 31.
The development of a vaccine against human respiratory syncytial virus (HRSV) has been hampered by enhanced respiratory disease due to the Th2-biased immune response. In the present study, MA103 and aluminum phosphate (Adju-Phos) adjuvants were used to verify the immunogenicity of the recombinant fusion (RBF) protein (F protein expressed by Escherichia coli). Both adjuvants significantly increased the neutralizing antibody titer and number of interferon gamma (IFN-γ)-secreting CD4+ T cells in mice. Based on the immunoglobulin G1 (IgG1)/IgG2a and IFN-γ/interleukin 4-secreting CD4+ T cell ratio, however, MA103 significantly enhanced the Th1-biased immune response. The pathological damage to the lung in the RBF/MA103 group was less than what was seen in the RBF/Adju-Phos group. Additionally, the number of HRSV copies in the lungs of the RBF/MA103 group decreased by approximately 3 × log. These results suggested that MA103 provides better protection against HRSV in mice.
一种针对人类呼吸道合胞病毒（HRSV）的疫苗的研发受到 Th2 偏向性免疫反应引起的增强性呼吸道疾病的阻碍。在本研究中，使用 MA103 和铝磷酸（Adju-Phos）佐剂来验证重组融合（RBF）蛋白（由大肠杆菌表达的 F 蛋白）的免疫原性。这两种佐剂都显著提高了小鼠的中和抗体滴度和分泌干扰素γ（IFN-γ）的 CD4+T 细胞数量。然而，基于 IgG1/IgG2a 和 IFN-γ/白细胞介素 4 分泌 CD4+T 细胞的比值，MA103 显著增强了 Th1 偏向性免疫反应。RBF/MA103 组的肺部病理损伤小于 RBF/Adju-Phos 组。此外，RBF/MA103 组肺部的 HRSV 拷贝数减少了约 3×log。这些结果表明，MA103 为小鼠提供了更好的 HRSV 保护。
